789 related articles for article (PubMed ID: 27766731)
21. Virologic response and safety of tenofovir versus entecavir in treatment-naïve chronic Hepatitis B patients.
Yu HM; Kwon SY; Kim J; Chung HA; Kwon SW; Jeong TG; An SH; Jeong GW; Yun SU; Min JK; Kim JH; Choe WH
Saudi J Gastroenterol; 2015; 21(3):146-51. PubMed ID: 26021773
[TBL] [Abstract][Full Text] [Related]
22. Tenofovir disoproxil fumarate monotherapy is superior to entecavir-adefovir combination therapy in patients with suboptimal response to lamivudine-adefovir therapy for nucleoside-resistant HBV: a 96-week prospective multicentre trial.
Lee SH; Cheon GJ; Kim HS; Kim SG; Kim YS; Jeong SW; Jang JY; Kim BS; Jun BG; Don Kim Y; Jun DW; Sohn JH; Kim TY; Lee BS
Antivir Ther; 2018; 23(3):219-227. PubMed ID: 28436380
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains.
Lee YB; Lee JH; Lee DH; Cho H; Ahn H; Choi WM; Cho YY; Lee M; Yoo JJ; Cho Y; Cho EJ; Yu SJ; Kim YJ; Yoon JH; Kim CY; Lee HS
Antimicrob Agents Chemother; 2014 Nov; 58(11):6710-6. PubMed ID: 25155601
[TBL] [Abstract][Full Text] [Related]
24. Switching to tenofovir disoproxil fumarate vs continuing treatment in patients with chronic hepatitis B who maintain long-term virological response to entecavir therapy: A randomized trial.
Iida-Ueno A; Enomoto M; Kozuka R; Tamori A; Kawada N
J Med Virol; 2019 Jul; 91(7):1295-1300. PubMed ID: 30815880
[TBL] [Abstract][Full Text] [Related]
25. Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies.
Kim HS; Yim HJ; Jang MK; Park JW; Suh SJ; Seo YS; Kim JH; Kim BH; Park SJ; Lee SH; Kim SG; Kim YS; Lee JI; Lee JW; Kim IH; Kim TY; Kim JW; Jeong SH; Jung YK; Park H; Hwang SG;
World J Gastroenterol; 2015 Oct; 21(38):10874-82. PubMed ID: 26478678
[TBL] [Abstract][Full Text] [Related]
26. Tenofovir rescue regimen following prior suboptimal response to entecavir and adefovir combination therapy in chronic hepatitis B patients exposed to multiple treatment failures.
Zhang Q; Han T; Nie CY; Ha FS; Liu L; Liu H
J Med Virol; 2015 Jun; 87(6):1013-21. PubMed ID: 25716029
[TBL] [Abstract][Full Text] [Related]
27. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.
Heo NY; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
J Hepatol; 2010 Sep; 53(3):449-54. PubMed ID: 20646776
[TBL] [Abstract][Full Text] [Related]
28. Tenofovir-based alternate therapies for chronic hepatitis B patients with partial virological response to entecavir.
Lu L; Yip B; Trinh H; Pan CQ; Han SH; Wong CC; Li J; Chan S; Krishnan G; Wong CC; Nguyen MH
J Viral Hepat; 2015 Aug; 22(8):675-81. PubMed ID: 25417914
[TBL] [Abstract][Full Text] [Related]
29. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ
World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545
[TBL] [Abstract][Full Text] [Related]
30. Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir.
Pan CQ; Hu KQ; Yu AS; Chen W; Bunchorntavakul C; Reddy KR
J Viral Hepat; 2012 Mar; 19(3):213-9. PubMed ID: 22329376
[TBL] [Abstract][Full Text] [Related]
31. No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B.
Corsa AC; Liu Y; Flaherty JF; Mitchell B; Fung SK; Gane E; Miller MD; Kitrinos KM
Clin Gastroenterol Hepatol; 2014 Dec; 12(12):2106-12.e1. PubMed ID: 24929235
[TBL] [Abstract][Full Text] [Related]
32. Comparison of lamivudine plus adefovir therapy versus entecavir with or without adefovir therapy for adefovir-resistant chronic hepatitis B.
Kang SH; Yim HJ; Kim HR; Kang K; Suh SJ; Lee HJ; Yoon EL; Kim JH; Seo YS; Yeon JE; Byun KS
J Clin Gastroenterol; 2014; 48(10):889-95. PubMed ID: 24440937
[TBL] [Abstract][Full Text] [Related]
33. Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B.
Park CH; Jung SW; Shin JW; Bae MA; Lee YI; Park YT; Chung HS; Park NH
Clin Mol Hepatol; 2016 Mar; 22(1):152-9. PubMed ID: 27044766
[TBL] [Abstract][Full Text] [Related]
34. Adefovir and lamivudine combination therapy in patients with entecavir-resistant chronic hepatitis B: antiviral responses and evolution of mutations.
Yim HJ; Lee HJ; Suh SJ; Seo YS; Kim CW; Lee CD; Park SH; Lee MS; Park CK; Chae HB; Kim MY; Baik SK; Kim YS; Kim JH; Lee JI; Lee JW; Hong SP; Um SH
Intervirology; 2014; 57(5):239-47. PubMed ID: 24993731
[TBL] [Abstract][Full Text] [Related]
35. Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naïve patients with chronic hepatitis B: a multicenter real-life study.
Batirel A; Guclu E; Arslan F; Kocak F; Karabay O; Ozer S; Turanli M; Mert A
Int J Infect Dis; 2014 Nov; 28():153-9. PubMed ID: 25286184
[TBL] [Abstract][Full Text] [Related]
36. Variability in the Responses of Hepatitis B Virus D-Subgenotypes to Antiviral Therapy: Designing Pan-D-Subgenotypic Reverse Transcriptase Inhibitors.
Khatun M; Kumar K; Baidya A; Mondal RK; Baszczyňski O; Kalčic F; Banerjee S; Dhali GK; Das K; Chowdhury A; Janeba Z; Chakrabarti S; Datta S
J Virol; 2022 Jan; 96(2):e0180021. PubMed ID: 34730399
[TBL] [Abstract][Full Text] [Related]
37. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
Cai S; Yu T; Jiang Y; Zhang Y; Lv F; Peng J
Clin Exp Med; 2016 Aug; 16(3):429-36. PubMed ID: 26164128
[TBL] [Abstract][Full Text] [Related]
38. Alternative Therapies for Chronic Hepatitis B Patients With Partial Virological Response to Standard Entecavir Monotherapy.
Chaung KT; O'Brien C; Ha NB; Nguyen NH; Trinh HN; Nguyen MH
J Clin Gastroenterol; 2016 Apr; 50(4):338-44. PubMed ID: 26646801
[TBL] [Abstract][Full Text] [Related]
39. Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B.
Chu M; Cho SM; Choe BH; Cho MH; Kwon S; Lee WK
J Pediatr Gastroenterol Nutr; 2012 Dec; 55(6):648-52. PubMed ID: 22688509
[TBL] [Abstract][Full Text] [Related]
40. Treatment Outcomes With First-line Therapies With Entecavir and Tenofovir in Treatment-Naive Chronic Hepatitis B Patients in a Routine Clinical Practice.
Ha NB; Trinh HN; Rosenblatt L; Nghiem D; Nguyen MH
J Clin Gastroenterol; 2016 Feb; 50(2):169-74. PubMed ID: 26018133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]